Drug Trial Radar · NCT03137173
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
679
Actual
Start
Feb 19, 2018
Primary completion
Apr 22, 2019
Study completion Apr 22, 2019
Sponsor
- Lead sponsor
- Basilea PharmaceuticaIndustry
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority
- First posted
- May 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
Conditions
- Acute Bacterial Skin and Skin Structure Infections
Interventions
ceftobiprole medocarilDrug
ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.
vancomycin+aztreonamDrug
Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor. Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was \< 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early Clinical ResponseTime frame: 48-72 hours after start of study drug treatment
Locations
34 sites in 4 countries. Site status is shown where the registry gives one.
Physician Alliance Research Center
Anaheim, California
Saint Joseph's Clinical Research
Anaheim, California
eStudySite - Chula Vista - PPDS
Chula Vista, California
Central Valley Research LLC
Fresno, California
Marvel Clinical Research
Huntington Beach, California
eStudySite - La Mesa - PPDS
La Mesa, California
Omnibus Clinical Research
La Palma, California
Alliance Research LLC
Long Beach, California
Long Beach Clinical Trials
Long Beach, California
Central Valley Research, LLC
Modesto, California
Gonzalez MD and Aswad MD Health Services
Coral Gables, Florida
L&C Professional Medical Research Institute
Miami, Florida
Mercury Street Medical Group
Butte, Montana
eStudySite - Las Vegas - PPDS
Las Vegas, Nevada
Excel Clinical Research
Las Vegas, Nevada
South Jersey Infectious Disease
Somers Point, New Jersey
University Multiprofile Hospital for Active Treatment
Pleven, Bulgaria
University Multiprofile Hospital for Active Treatment
Plovdiv, Bulgaria
University Multiprofile Hospital for Active Treatment
Rousse, Bulgaria
"University Multiprofile Hospital for Active Treatment and Emergency Medicine ""N. I. Pirogov"", Clinic of Purulent-Septic Surgery-"N.I. Pirogov""
Sofia, Bulgaria
Kaposi Mor Teaching Hospital
Kaposvár, Hungary
CRU Hungary Ltd.
Miskolc, Hungary
University of SzegednAlbert Szent-Gyorgyi Clinical Center
Szeged, Hungary
Csolnoky Ferenc Hospital
Veszprém, Hungary
Dnipropetrovsk I.I. Mechnуkov Regional Clinical Hospital, Surgery Department #2
Dnipro, Ukraine
Ivano-Frankivsk City Clinical Hospital Surgery 1
Ivano-Frankivsk, Ukraine
Ivano-Frankivsk City Clinical Hospital General Surgery
Ivano-Frankivsk, Ukraine
Kyiv City Clinical Hospital
Kyiv, Ukraine
Public City Clinical Hospital of Emergency Medical Care
Lviv, Ukraine
Lviv Regional Clinical Hospital
Lviv, Ukraine
Central City Clinical Hospital
Uzhhorod, Ukraine
Vinnytsia M.I. Pyrohov Regional Clinical Hospital
Vinnytsia, Ukraine
Zaporizhia City Clinical Hospital of Urgent and Emergency Medical Care
Zaporizhia, Ukraine
Central District Hospital
Zhytomyr, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.